Shov­ing Re­genxbio aside, Ul­tragenyx’s Emil Kakkis clos­es Di­men­sion buy­out deal with 400% pre­mi­um

Ul­tragenyx $RARE has won its 11th-hour bid for the trou­bled gene ther­a­py biotech Di­men­sion Ther­a­peu­tics $DMTX, which is leav­ing Re­genxbio $RGNX at the al­tar.

Scut­tled by a clin­i­cal dis­as­ter for its he­mo­phil­ia B pro­gram, Di­men­sion was ready to hand over the rest of the pipeline to Re­genxbio for $3.41 a share, a hefty pre­mi­um for its bad­ly bat­tered stock.

But Ul­tragenyx CEO Emil Kakkis — an ad­vis­er to Di­men­sion — clear­ly felt it still looked like a bar­gain.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.